Free Access
Issue
J Extra Corpor Technol
Volume 49, Number 2, June 2017
Page(s) 115 - 120
DOI https://doi.org/10.1051/ject/201749115
Published online 15 June 2017
  1. Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373:252–61. [CrossRef] [PubMed] [Google Scholar]
  2. Brodie D., Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med. 2011;365:1905–14. [CrossRef] [PubMed] [Google Scholar]
  3. Extracorporeal Life Support Organization ELSO anticoagulation guideline. 2014 Available at: http://www.elso.org/Portals/0/Files/elsoanticoagulationguideline8-2014-table-contents.pdf. [Google Scholar]
  4. Welp H., Ellger B., Scherer M., Lanckohr C., Martens S., Gottschalk A. Heparin-induced thrombocytopenia during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth. 2014;28:342–4. [CrossRef] [PubMed] [Google Scholar]
  5. Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2016. [Google Scholar]
  6. Ratzlaff R. A., Ripoll J. G., Kassab L. L., Diaz-Gomez J. L. Acute oxygenator failure: A new presentation of heparin-induced thrombocytopenia in a patient undergoing venovenous extracorporeal membrane oxygenation support. BMJ Case Rep. 2016 doi:10.1136/bcr-2016-218179. [PubMed] [Google Scholar]
  7. Phillips M. R., Khoury A. I., Ashton R. F., Cairns B. A., Charles A. G. The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: A word of caution. Anaesth Intensive Care. 2014;42:97–8. [CrossRef] [PubMed] [Google Scholar]
  8. Kuhl T., Wendt S., Langebartels G., Kroner A., Wahlers T. Recurrent left atrial and left ventricular thrombosis due to heparin-induced thrombocytopenia: Case report and short review. Thorac Cardiovasc Surg. 2013;61:537–40. [CrossRef] [PubMed] [Google Scholar]
  9. Dolch M. E., Frey L., Hatz R., et al. Extracorporeal membrane oxygenation bridging to lung to transplant complicated by heparin-induced thrombocytopenia. Exp Clin Transplant. 2010;8:329–32. [PubMed] [Google Scholar]
  10. Cornell T., Wyrick P., Fleming G., et al. A case series describing the use of argatroban in patients on extracorporeal circulation. ASAIO J. 2007;53:460–3. [CrossRef] [PubMed] [Google Scholar]
  11. Beiderlinden M., Treschan T., Gorlinger K., Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs. 2007;31:461–5. [CrossRef] [PubMed] [Google Scholar]
  12. Johnston N., Wait M., Huber L. Argatroban in adult extracorporeal membrane oxygenation. J Extra Corpor Technol. 2002;34:281–4. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Shekar K., Fraser J. F., Smith M. T., Roberts J. A. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27:741. [Google Scholar]
  14. Keegan S. P., Gallagher E. M., Ernst N. E., Young E. J., Mueller E. W. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother. 2009;43:19–27. [CrossRef] [PubMed] [Google Scholar]
  15. Saugel B., Phillip V., Moessmer G., Schmid R. M., Huber W. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: A retrospective study. Crit Care. 2010;14:R90. [CrossRef] [PubMed] [Google Scholar]
  16. Smythe M. A., Koerber J. M., Forsyth L. L., Priziola J. L., Balasubramaniam M., Mattson J. C. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients. Pharmacotherapy. 2009;29:1073–81. [CrossRef] [PubMed] [Google Scholar]
  17. Begelman S. M., Baghdasarin S. B., Singh I. M., Militello M. A., Hursting M. J., Bartholomew J. R. Argatroban anticoagulation in intensive care patients: Effects of heart failure and multiple organ system failure. J Intensive Care Med. 2008;23:313–20. [CrossRef] [PubMed] [Google Scholar]
  18. Beiderlinden M., Treschan T. A., Gorlinger K., Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007;41:749–54. [CrossRef] [PubMed] [Google Scholar]
  19. Smith B. S., Yogaratnam D., Levasseur-Franklin K. E., Forni A., Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012;141:1327–36. [CrossRef] [PubMed] [Google Scholar]
  20. Boucher B. A., Wood G. C., Swanson J. M. Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22:255–71. [CrossRef] [PubMed] [Google Scholar]
  21. Abel E. E., Kane-Gill S. L., Seybert A. L., Kellum J. A. Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes. Am J Health Syst Pharm. 2012;69:1559–67. [CrossRef] [PubMed] [Google Scholar]
  22. Hursting M. J., Murray P. T. Argatroban anticoagulation in renal dysfunction: A literature analysis. Nephron Clin Pract. 2008;109:c80–94. [CrossRef] [PubMed] [Google Scholar]
  23. Reddy B. V., Grossman E. J., Trevino S. A., Hursting M. J., Murray P. T. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother. 2005;39:1601–5. [CrossRef] [PubMed] [Google Scholar]
  24. Tang I. Y., Cox D. S., Patel K., et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2005;39:231–6. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.